IN2014DN10558A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10558A
IN2014DN10558A IN10558DEN2014A IN2014DN10558A IN 2014DN10558 A IN2014DN10558 A IN 2014DN10558A IN 10558DEN2014 A IN10558DEN2014 A IN 10558DEN2014A IN 2014DN10558 A IN2014DN10558 A IN 2014DN10558A
Authority
IN
India
Prior art keywords
amino acid
acid sequence
polypeptide
salt
cell epitope
Prior art date
Application number
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Pascal Hickey
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46582267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of IN2014DN10558A publication Critical patent/IN2014DN10558A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
IN10558DEN2014 2012-06-01 2013-05-30 IN2014DN10558A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209868.7A GB201209868D0 (en) 2012-06-01 2012-06-01 Alternaria peptides
PCT/GB2013/051439 WO2013179043A1 (en) 2012-06-01 2013-05-30 Alternaria peptides

Publications (1)

Publication Number Publication Date
IN2014DN10558A true IN2014DN10558A (enExample) 2015-08-21

Family

ID=46582267

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10558DEN2014 IN2014DN10558A (enExample) 2012-06-01 2013-05-30

Country Status (17)

Country Link
US (1) US20150098969A1 (enExample)
EP (1) EP2855515A1 (enExample)
JP (1) JP2015520771A (enExample)
KR (1) KR20150028788A (enExample)
CN (1) CN104507959A (enExample)
AU (1) AU2013269326A1 (enExample)
BR (1) BR112014029856A2 (enExample)
CA (1) CA2875130A1 (enExample)
CL (1) CL2014003290A1 (enExample)
EA (1) EA201492268A1 (enExample)
GB (2) GB201209868D0 (enExample)
HK (1) HK1201752A1 (enExample)
IL (1) IL235840A0 (enExample)
IN (1) IN2014DN10558A (enExample)
MX (1) MX2014014461A (enExample)
SG (1) SG11201407975TA (enExample)
WO (1) WO2013179043A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003365A1 (en) * 2013-06-05 2016-04-13 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400723B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
JP2007176953A (ja) * 1996-03-10 2007-07-12 Meiji Milk Prod Co Ltd アレルギー疾患に対するペプチド免疫療法剤
JP2003116556A (ja) * 2001-10-09 2003-04-22 Nippon Zenyaku Kogyo Kk アレルギー性皮膚炎治療剤
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
WO2009022154A2 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2982684A1 (en) * 2010-09-24 2016-02-10 Maria R. Diaz-Torres Peptides deriving from Alternaria Alternata major allergen Alt a 1

Also Published As

Publication number Publication date
EP2855515A1 (en) 2015-04-08
AU2013269326A1 (en) 2014-12-18
IL235840A0 (en) 2015-01-29
US20150098969A1 (en) 2015-04-09
MX2014014461A (es) 2015-02-10
KR20150028788A (ko) 2015-03-16
SG11201407975TA (en) 2015-01-29
CL2014003290A1 (es) 2015-05-22
WO2013179043A1 (en) 2013-12-05
EA201492268A1 (ru) 2015-05-29
CN104507959A (zh) 2015-04-08
JP2015520771A (ja) 2015-07-23
GB201209868D0 (en) 2012-07-18
BR112014029856A2 (pt) 2017-07-25
CA2875130A1 (en) 2013-12-05
HK1201752A1 (en) 2015-09-11
GB2517871A (en) 2015-03-04

Similar Documents

Publication Publication Date Title
GB201206559D0 (en) Polypeptide
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
IN2012DE00337A (enExample)
IN2014DN09963A (enExample)
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
IN2014DN06920A (enExample)
EA033437B9 (ru) Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
IN2015DN00585A (enExample)
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
PH12017502323B1 (en) Novel xylanase
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
IN2014DN10558A (enExample)
GB201018125D0 (en) Peptide
NZ618125A (en) Genetic vaccines against hendra virus and nipah virus
GB2518092A (en) Cladosporium peptides
WO2012102625A3 (en) Therapeutic composition
WO2014174520A8 (en) Use of inhibitory peptides for the treatment of inflammatory diseases